Skip to content
DataLookout
Menu

NCT06260033

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 29, 2026 to Oct 29, 2027
  2. Notable Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Study description revised
  3. Minor Start date changed from estimate of Sep 11, 2024 to Jul 23, 2024v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Dec 11, 2025 to Oct 29, 2026
    • Start date: Jun 11, 2024 to Sep 11, 2024
    • Site details revised at 2 of 2 sites
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients that remain on their original systemic therapy for at least ≥ 24 weeks post stereotactic body radiation therapy (SBRT) treatment
Timeframe: Up to 24 weeks post SBRT treatment

Secondary (5)

Rate of all grades and grade ≥ 3 toxicities at least possibly related to study therapy
Number of lesions found on F-18 16 alpha fluoroestradiol positron emission tomography (FES-PET)
Change in quality of life (QOL)
Time to next line of systemic therapy
Progression free survival (PFS)

Arms and interventions

Treatment (SBRT, FES PET/CT)Experimental

Patients currently taking SERMs/ SERDs immediately undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. Patients not currently taking SERMs/SERDs first receive F-FES IV and undergo PET/CT scans at baseline. After baseline FES PET/CT, patients with ≤ 4 sites of progressive disease then undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. All patients undergo FES PET/CT at 12 and 24 weeks. Patients with SD after 12 or 24 week FES PET/CT may continue standard systemic therapy. Patients with ≤ 4 sites of progressive disease after 12 or 24 week FES PET/CT may receive SBRT to additional sites in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. All patients also undergo CT, PET/CT, or bone scans, and blood samples collection during screening and on study.

Procedures: Biospecimen Collection, Bone Scan, Computed Tomography, Positron Emission Tomography

Drugs: F-18 16 Alpha-Fluoroestradiol

Other: Questionnaire Administration

Radiation: Stereotactic Body Radiation Therapy

Sites

2 sites in 1 country